PER® Chemotherapy Foundation Symposium (CFS) | Conference

Dr. Mascarenhas on the Promise of Imetelstat in Myelofibrosis

November 4th 2020

John O. Mascarenhas, MD, discusses the promise of imetelstat in myelofibrosis.

Dr. Pemmaraju on a New Era of Treatment Strategies in BPDCN

November 4th 2020

Naveen Pemmaraju, MD, discusses current treatment strategies in blastic plasmacytoid dendritic cell neoplasm.

Dr. Lonial on the Advantage of Targeting BCMA in Multiple Myeloma

November 4th 2020

Sagar Lonial, MD, FACP, discusses the advantage of targeting BCMA in multiple myeloma.

Mato Presents Sequencing Framework for Crowded CLL Landscape

November 4th 2020

An explosion of therapeutic options for chronic lymphocytic leukemia has resulted in challenging questions about sequencing therapies for patients who progress after frontline treatment with little data to guide optimal therapy selection.

Choosing the Optimal Frontline Approach for Low-Grade Follicular Lymphoma

November 4th 2020

Frontline treatment decisions for patients with follicular lymphoma can be guided by a general framework; the choice of therapy is often based on several factors such as indications of therapy, bulk of disease, comorbidities, and toxicity.

New Strategies Improve Outcomes for Lower-Risk MDS

November 4th 2020

Myelodysplastic syndrome is a challenging and complicated disease with median outcomes ranging from 5.3 years in patients with lower-risk disease to just 8.4 months in the very high-risk population.

BCMA-Targeting Drugs Take Center Stage in Myeloma

November 4th 2020

The treatment landscape for multiple myeloma is poised to enter a new era of innovation with the development of therapies that target B-cell maturation antigen, which is highly expressed on plasma and MM cells.

Dr. O'Regan on Prognostic Value of pCR in HER2+ Breast Cancer

November 9th 2019

Ruth O’Regan, MD, discusses the prognostic value of pathologic complete response in HER2-positive breast cancer.

Dr. Oh on Choosing AR-Targeted Therapy Versus Chemotherapy in mHSPC

November 8th 2019

William K. Oh, MD, discusses factors to consider when choosing a treatment for patients with metastatic hormone-sensitive prostate cancer.

Dr. Brufsky on Challenges in Breast Cancer Treatment

November 8th 2019

Adam M. Brufsky, MD, PhD, discusses remaining challenges in breast cancer.

Dr. Luke on Treatment Options in Metastatic Melanoma

November 8th 2019

Jason J. Luke, MD, FACP, discusses the treatment landscape of metastatic melanoma.

Expert Compares Frontline Immunotherapy Studies in RCC

November 8th 2019

Three game-changing immunotherapy trials have transformed the treatment paradigm in frontline clear cell renal cell carcinoma. At the 37th Annual CFS®, Robert J. Motzer, MD, compared the findings from the three studies.

Efforts Continue to Perfect PARPi Use in Ovarian Cancer

November 8th 2019

As PARP inhibitors have now moved into the frontline maintenance setting in ovarian cancer, researchers are now seeking to even further capitalize on use of these agents, including indications in treatment-naïve patients.

Adjuvant Immunotherapy Combinations on Horizon for Melanoma

November 8th 2019

Quickly following on the approval of single agents, adjuvant immunotherapy combinations are quickly progressing through development, with promising signs of clinical activity seen in phase II studies, according to a presentation by Jeffrey S. Weber, MD, PhD, at the 37th Annual CFS®.

Dr. Furman on Prognostic Markers in High-Risk CLL

November 7th 2019

Richard R. Furman, MD, discusses the role of prognostic markers in high-risk chronic lymphocytic leukemia.

Dr. Motzer on First-Line Treatment of Metastatic RCC

November 7th 2019

Robert J. Motzer, MD, discusses the first-line treatment landscape of metastatic clear cell renal cell carcinoma.

Novel Combinations Could Improve Cure Rates for Adult ALL

November 7th 2019

Novel combinations of biologic therapies, third-generation TKIs, and chemotherapy could lead to significantly higher cure rates for adult patients with acute lymphoblastic leukemia, with a number of early stage studies already showing promising results, according to Hagop M. Kantarjian, MD, at the 37th Annual CFS®.

Expert Explains Treatment Considerations in Newly Diagnosed Follicular Lymphoma

November 7th 2019

Given that a watch-and-wait approach is a viable option, clinicians must carefully consider disease characteristics when selecting a treatment strategy in newly diagnosed follicular lymphoma.

Anti-BCMA Approaches Ascending in Multiple Myeloma

November 7th 2019

Anti-BCMA directed treatments, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates, have the potential to revolutionize the multiple myeloma treatment paradigm. At the 37 Annual CFS®, Sham Mailankody, MBBS, discussed the emerging BCMA-directed therapies that have shown the greatest potential.

Immunotherapy Approval Offers New Hope in CSCC

November 9th 2018

Treatment for cutaneous squamous cell carcinoma (CSCC) took a great leap forward in September 2018 with the PD-1 inhibitor cemiplimab becoming the first agent specifically approved by the FDA for advanced CSCC.